Title
Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis
A Phase 1/2, Randomized, Double-Blinded, Placebo-Controlled, Combined Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Biological Activity of MRT5005 Administered by Nebulization to Adult Subjects With Cystic Fibrosis
Phase
Phase 1/Phase 2Lead Sponsor
Translate Bio, Inc.Study Type
InterventionalStatus
Unknown statusIndication/Condition
Cystic FibrosisIntervention/Treatment
MRT5005 ...Study Participants
40This Phase 1/2, first-in-human study will evaluate the safety and tolerability of single and multiple escalating doses of MRT5005 administered by nebulization to the respiratory tract of adult subjects with CF.
Nebulization of MRT5005
Normal Saline for Inhalation
Inclusion Criteria: Confirmed diagnosis of CF as defined by both of the following: Two CF disease-causing CFTR mutations in Class I or II (genotype confirmed at the screening visit). Chronic sinopulmonary disease and/or gastrointestinal/nutritional abnormalities consistent with CF disease. Clinically stable CF disease, as judged by the investigator. FEV1 ≥50% and ≤90% of the predicted normal for age, gender, and height at screening. Resting oxygen saturation ≥92% on room air (pulse oximetry). Exclusion Criteria: An acute upper or lower respiratory infection, pulmonary exacerbation, clinically significant episode of hemoptysis or change in chronic respiratory medications (including antibiotics) for CF lung disease within 28 days prior to dosing with investigational product on Day 1. Receiving treatment with ivacaftor monotherapy (KALYDECO) For all groups except Daily dosing: Receiving treatment with triple combination therapy (TRIKAFTA). Subjects with a Class III, IV, or V CFTR gene mutation in at least 1 allele. Infection with highly virulent bacteria associated with accelerated decline in pulmonary function and/or decreased survival (e.g., Burkholderia cenocepacia, Burkholderia dolosa, Mycobacterium abscessus). Treatment with ORKAMBI or SYMDEKO is not an exclusion for this study.
